3-(benzo[d]thiazol-2-yl)-4-(4-methoxyphenyl)butanoic acid

ID: ALA4877010

PubChem CID: 164627265

Max Phase: Preclinical

Molecular Formula: C18H17NO3S

Molecular Weight: 327.41

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  COc1ccc(CC(CC(=O)O)c2nc3ccccc3s2)cc1

Standard InChI:  InChI=1S/C18H17NO3S/c1-22-14-8-6-12(7-9-14)10-13(11-17(20)21)18-19-15-4-2-3-5-16(15)23-18/h2-9,13H,10-11H2,1H3,(H,20,21)

Standard InChI Key:  ZQVFOKXWXIXJSC-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
   27.7294  -22.7988    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.7283  -23.6183    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.4363  -24.0273    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.4345  -22.3899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.1432  -22.7952    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.1434  -23.6138    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.9221  -23.8666    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   30.4031  -23.2041    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.9216  -22.5420    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   31.2203  -23.2038    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.6291  -23.9113    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.2208  -24.6192    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.4036  -24.6195    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   31.6297  -25.3268    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   31.6286  -22.4959    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.4458  -22.4956    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.8503  -23.2044    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.6667  -23.2044    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.0759  -22.4961    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.6626  -21.7862    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.8475  -21.7896    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.8930  -22.4947    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   35.3028  -23.2017    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  6  2  0
  5  4  2  0
  4  1  1  0
  5  6  1  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9  5  1  0
  8 10  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 12 14  2  0
 10 15  1  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 16  1  0
 19 22  1  0
 22 23  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4877010

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 327.41

Molecular Weight (Monoisotopic): 327.0929

AlogP: 4.11

#Rotatable Bonds: 6

Polar Surface Area: 59.42

Molecular Species: ACID

HBA: 4

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 4.49

CX Basic pKa: 1.82

CX LogP: 4.03

CX LogD: 1.21

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.74

Np Likeness Score: -0.70

References

1. Azuma M, Inoue M, Nishida A, Akahane H, Kitajima M, Natani S, Chimori R, Yoshimori A, Mano Y, Uchiro H, Tanuma SI, Takasawa R..  (2021)  Addition of hydrophobic side chains improve the apoptosis inducibility of the human glyoxalase I inhibitor, TLSC702.,  40  [PMID:33711442] [10.1016/j.bmcl.2021.127918]

2. Arora S, Joshi G, Chaturvedi A, Heuser M, Patil S, Kumar R..  (2022)  A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.,  65  (2.0): [PMID:34726055] [10.1021/acs.jmedchem.1c00981]

3. Rathod B, Chak S, Patel S, Shard A..  (2021)  Tumor pyruvate kinase M2 modulators: a comprehensive account of activators and inhibitors as anticancer agents.,  12  (7.0): [PMID:34355179] [10.1039/D1MD00045D]

Source

Source(1):

• Scientific Literature